Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors.
Growth of tumors is strongly dependent upon supply of nutrients and oxygen by de novo formed blood vessels. Inhibiting angiogenesis suppresses growth of primary tumors as well and affects development of metastases. We demonstrate that recombinant MBP/vasostatin fusion protein inhibits proliferation of endothelial cells in vitro. The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas. In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice. A combination therapy involving MBP/vasostatin construct and cyclophosphamide was even more effective and led to further inhibition of the tumor growth and extended survival. We show that such combination might be useful in the clinical setting, especially to treat tumors which have already formed microvessel networks.
Jazowiecka-Rakus
Joanna
J
Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
Jarosz
Magdalena
M
Kozłowska
Dorota
D
Sochanik
Aleksander
A
Szala
Stanisław
S
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D037282:Calreticulin / Q000235:genetics / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D010446:Peptide Fragments / Q000235:genetics / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D016019:Survival Analysis
D020533:Angiogenesis Inhibitors; D037282:Calreticulin; D010446:Peptide Fragments; D011993:Recombinant Fusion Proteins; C121986:vasostatin; D003520:Cyclophosphamide